Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-0.21 |
-0.18 |
0.03 |
14.29% |
2024-03-04 |
2023-12 |
-0.2 |
-0.22 |
-0.02 |
-10.00% |
2023-11-07 |
2023-09 |
-0.18 |
-0.19 |
-0.01 |
-5.56% |
2023-08-08 |
2023-06 |
-0.3 |
-0.27 |
0.03 |
10.00% |
2023-05-09 |
2023-03 |
-0.26 |
-0.25 |
0.01 |
3.85% |
2023-02-28 |
2022-12 |
-0.45 |
-0.32 |
0.13 |
28.89% |
Date |
Firm |
Action |
From |
To |
2023-08-06 |
Mizuho |
Upgrade |
|
Neutral |
2023-05-09 |
Jefferies |
Upgrade |
Underperform |
Hold |
2023-03-05 |
Oppenheimer |
Upgrade |
|
Perform |
2023-02-26 |
Goldman Sachs |
Upgrade |
|
Sell |
2023-02-23 |
SVB Leerink |
Upgrade |
|
Market Perform |
2023-02-23 |
Jefferies |
Downgrade |
Hold |
Underperform |
Date |
Name |
Relation |
Quantity |
Description |
2023-09-17 |
AJER JEFF ROBERT |
Director |
34.15K |
Sale |
2022-09-21 |
CHESS ROBERT BRUCE |
Director |
291.27K |
Sale |
2023-09-17 |
CURET MYRIAM J |
Director |
27.42K |
Sale |
2024-05-09 |
DEEP TRACK CAPITAL LP |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2022-09-15 |
GREER R SCOTT |
Director |
303.57K |
Stock Award(Grant) |
2024-05-16 |
ROBIN HOWARD W |
Chief Executive Officer |
863.65K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Deep Track Capital, Lp |
17.97M |
10.34M |
9.45% |
2023-06-29 |
Vanguard Group Inc |
12.06M |
6.93M |
6.34% |
2023-06-29 |
Citadel Advisors Llc |
9.70M |
5.58M |
5.10% |
2023-06-29 |
Monaco Asset Management SAM |
9.26M |
5.33M |
4.87% |
2023-06-29 |
Shaw D.E. & Co., Inc. |
9.15M |
5.26M |
4.81% |
2023-06-29 |
Blackrock Inc. |
8.60M |
4.95M |
4.53% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
5.85M |
3.36M |
3.08% |
2023-07-30 |
Primecap Odyssey Aggressive Growth Fund |
4.25M |
2.28M |
2.24% |
2023-06-29 |
Vanguard Extended Market Index Fund |
2.68M |
1.54M |
1.41% |
2023-07-30 |
Primecap Odyssey Growth Fund |
2.16M |
1.16M |
1.14% |
2023-06-29 |
Vanguard Strategic Equity Fund |
1.52M |
872.64K |
0.80% |
2023-08-30 |
iShares NASDAQ Biotechnology ETF |
1.28M |
762.81K |
0.67% |
Split |
Date |
2 : 1 |
2000-08-23 |